We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82...
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice...
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris...
Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire L’étude de phase III LUNA 3...
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal...
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte...
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en...
Sanofi: Information concerning the total number of voting rights and shares - March 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mars 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -0.097857997173 | 91.97 | 94.03 | 90.62 | 1320345 | 92.15174986 | DE |
4 | 5.36 | 6.19509939898 | 86.52 | 94.03 | 85.07 | 1456912 | 89.06761395 | DE |
12 | 5.88 | 6.83720930233 | 86 | 94.03 | 84.93 | 1384099 | 88.48331236 | DE |
26 | 7.38 | 8.73372781065 | 84.5 | 96.5 | 82.86 | 1431979 | 88.55637004 | DE |
52 | -9 | -8.92149088025 | 100.88 | 104.32 | 80.6 | 1432390 | 92.77813299 | DE |
156 | 7.27 | 8.59236496868 | 84.61 | 106.66 | 76.45 | 1794447 | 91.20353104 | DE |
260 | 15.01 | 19.5264732666 | 76.87 | 106.66 | 67.65 | 2048259 | 87.36961724 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions